Document:

Exhibit 10.21

 Exhibit 10.21 
 Statement of Work for MAP Feasibility Project 
  

			
	PARTIES:	 	Universal Biosensors Pty Ltd (“UBS”) and Cilag GmbH International (“Cilag”)
		
	 REFERENCE:
	 	The parties shall perform the following Project under the terms and conditions of the Amended and Restated Development & Research Agreement between Cilag and UBS dated
August 19, 2011 as follows.
		
	PROJECT TITLE:	 	MAP Feasibility Project (“Project”)
		
	OBJECTIVE:	 	Demonstration of the technical feasibility of developing a MAP strip based on Gemini technology.

 TERM OF WORK: Twelve (12) consecutive months beginning as of the date this SOW is executed by all of the
parties, or as terminated earlier or extended as set forth herein. 
 SCOPE OF WORK AND DELIVERABLES: See Attachment A attached hereto
and made a part hereof. 
 TEAM MEMBERS: The core team members from Cilag will be *[REDACTED] and *[REDACTED] and from UBS
will be *[REDACTED] and *[REDACTED]. 
 TIMELINE, COSTS AND PAYMENT: 

FEES: The fees payable by Cilag to UBS for the Project will be US$4.5 million, subject to increase in accordance with the terms of this SOW. UBS
acknowledges that Cilag has paid US $250,000 of the US$4.5 million prior to execution of this SOW for work begun prior to such execution. The payments corresponding to the milestone set out in the table below shall be made within 45 days of
completion of the relevant milestone. 
 In the event that UBS and Cilag, at any time, mutually agree that feasibility will not be achieved
based on the stated milestones in the table below and the milestone metrics set forth on Attachment A, the Project will be terminated and no payments will be due from Cilag for milestones not achieved prior to the termination date. 

CAPITAL EXPENDITURES: UBS capital expenditures for the Project shall not exceed US$1.2 million without approval by Cilag. UBS will recover its
capital expenditure costs from Cilag against supplier invoices incurred by UBS. Payment must be made by Cilag to UBS in accordance with the supplier’s terms so that UBS can pay the supplier invoices when due. 

All capital equipment purchased by UBS and paid for by Cilag shall be the sole property of Cilag and shall be: 

a.) subject to removal at any time upon Cilag’s demand provided that such removal does not prevent UBS from fulfilling its
obligations under this SOW if this SOW is still in force between the parties after the removal; 
 b.) used only for the purposes
of the Project and as otherwise directed by Cilag; 
  

	*	Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

 c.) maintained in good condition (protection, calibration, maintenance and care, other than
normal wear and tear) and secured against loss and damage in the same manner as UBS secures its own equipment; 
 d.) identified
clearly as the sole property of Cilag by indicating on them as belonging to “Cilag GmbH International.” in a way as to put creditors or others on notice that Cilag retains title thereto. 

At the conclusion of the Project and for a period of 45 days thereafter, Cilag may at its sole discretion and expense, determine that the equipment must
be returned to Cilag. If Cilag does not request the return of the equipment within the 45 day period, then UBS may, at Cilag’s cost, return the equipment to Cilag, dispose of the equipment, or negotiate reasonable terms with Cilag for retaining
the equipment. 
 SCHEDULE: At the completion of each milestone of the schedule set forth below, a revised completion date for the
Project will be provided to Cilag by UBS. In the event that the Project is not completed on or before the end of the twelve month period of the Project term the term shall be extended from month-to-month and the additional fees for each additional
month will be as follows: 
  

	 	•	 	 At the end of each thirty (30) day extension period of the Project term, UBS will invoice Cilag for **[REDACTED] percent
(**[REDACTED]%) of the pro-rata monthly cost of the initial 12 month Project term (**$4.25 million). For the avoidance of doubt, milestone fees will also be payable with respect to any milestones achieved during this extension period
of the Project term. 

  

	 	•	 	 If feasibility has not been achieved by the end of the Project term, either party may terminate the Project and this SOW at anytime with 1 month’s
prior, written notice to the other party. The obligation for Cilag to pay UBS for any milestones completed prior to termination survives the termination or expiration of this SOW. 

 

													
	 Milestone/Activity
	  	Indicative Start
Date*	 	 	Indicative Finish
Date*	 	 	Payment
(US$‘000)	 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 *[REDACTED]
	  	 	*[REDACTED	] 	 	 	*[REDACTED	] 	 	 	*[REDACTED	] 
	 TOTAL PROJECT
	  				 				 	 	4,25	  

  

	*	All Project dates in this SOW are for planning purposes only and are subject to change. A milestone does not need to be achieved within the indicative timeframes in
order for milestone payment obligations to arise. 

  

	**	Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

  
 2 

 ACCEPTANCE OF STATEMENT OF WORK DESCRIPTION AND TERMS: 

UNIVERSAL BIOSENSORS PTY LTD 

 

			
	By:	 	     /s/ Salesh
Balak

			
		
	Name:	 	 Salesh Balak

			
		
	Title:	 	 Director

			
		
	Date:	 	 October 11, 2011

 

 
 

  
 CILAG GMBH INTERNATIONAL

 

			
	By:	 	     /s/ Heinz
Schmid

			
		
	Name:	 	 Heinz Schmid

			
		
	Title:	 	   General Manager

			
		
	Date:	 	 September 19, 2011

 

			
	By:	 	  /s/ Christian Cuzick

			
		
	Name:	 	  /s/ Christian Cuzick

			
		
	Title:	 	  Finance Director

			
		
	Date:	 	  September 27, 2011

 
 

 Milestone definition 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 
 *[REDACTED] 

 

											
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
						
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]
	 *[REDACTED]
	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]	 	*[REDACTED]

  

	*	Confidential portion has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.

  
 4Officers' Certificate of Berkshire Hathaway Inc., dated January 31, 2012

 Exhibit 4.2 
 BERKSHIRE HATHAWAY INC. 
 OFFICERS’ CERTIFICATE 

ESTABLISHING TERMS OF NOTES 
 January 31, 2012 
 The undersigned, Marc D. Hamburg and Robert P.
Reeson, do hereby certify pursuant to the authority granted in the resolutions adopted by the Board of Directors of Berkshire Hathaway Inc. (the “Corporation”) on January 29, 2010, and pursuant to Section 3.01 of that
certain Indenture, dated as of February 1, 2010, among the Corporation, Berkshire Hathaway Finance Corporation and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Indenture”) that: 

1. They are (i) the Senior Vice President and Chief Financial Officer and (ii) the Assistant Secretary, respectively, of the
Corporation. 
 2. As such officers, they are authorized to execute and deliver this Officers’ Certificate on behalf of the
Corporation. 
 3. Attached hereto as Annex A is a true and correct copy of a specimen note representing the Corporation’s
1.90% Senior Notes due 2017 (the “2017 Senior Notes”); and attached hereto as Annex B is a true and correct copy of a specimen note representing the Corporation’s 3.40% Senior Notes due 2022 (the “2022 Senior
Notes”). 
 4. The 2017 Senior Notes and the 2022 Senior Notes are each a separate series of Securities under the
Indenture and are referred to herein collectively as the “Notes.” The forms of Notes attached hereto as Annex A and Annex B are incorporated herein by reference. 
 5. The title of the 2017 Senior Notes shall be the “1.90% Senior Notes due 2017”; and the title of the 2022 Senior Notes shall be the “3.40% Senior Notes due 2022.” Each series of
Notes will be the Corporation’s unsecured senior obligations, will rank pari passu in right of payment with all of the Corporation’s unsubordinated, unsecured indebtedness and will be Senior in right of payment to all of the
Corporation’s subordinated indebtedness. 
 6. The 2017 Senior Notes shall be issued at the initial offering price of
99.995% of the principal amount; and the 2022 Senior Notes shall be issued at the initial offering price of 99.723% of the principal amount. 
 7. The Corporation will initially issue $1,100,000,000 aggregate principal amount of 2017 Senior Notes; and $600,000,000 aggregate principal amount of 2022 Senior Notes. The Corporation may issue
additional 2017 Senior Notes and/or 2022 Senior Notes from time to time after the date hereof, and such Notes will be treated as part of the respective series of Notes for all purposes under the Indenture. 

8. The principal amount of the 2017 Senior Notes will mature on January 31, 2017; and the principal amount of the 2022 Senior Notes
will mature on January 31, 2022. 

  
 - 1 -

 9. The Notes are issuable in minimum denominations of $2,000 and integral multiples of
$1,000 in excess thereof. 
 10. Interest on the Notes will be computed on the basis of a 360 day year of twelve 30-day months.

 11. The 2017 Senior Notes will bear interest from January 31, 2012 at the rate of 1.90% per annum, payable on each
January 31 and July 31, commencing July 31, 2012, to the holders of record of the 2017 Senior Notes on the January 15 or July 15, as the case may be, immediately preceding such January 31 or July 31. 

12. The 2022 Senior Notes will bear interest from January 31, 2012 at the rate of 3.40% per annum, payable on each
January 31 and July 31, commencing July 31, 2012, to the holders of record of the 2022 Senior Notes on the January 15 or July 15, as the case may be, immediately preceding such January 31 or July 31. 

13. Payment of the principal of and interest on the Notes will be made at the office or agency of the Corporation maintained for that
purpose in the City of New York, New York (or, if the Corporation does not maintain such office or agency, at the corporate trust office of the Trustee in the City of New York or if the Trustee does not maintain an office in the City of New York, at
the office of a Paying Agent in the City of New York), in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debt; provided, however, that at the option of the
Corporation payments of principal or interest may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register. 
 14. The Notes will initially be issued in the form of one or more Global Securities. The Depository Trust Company shall serve as the Depositary for such Global Securities. 

15. The Notes shall be defeasible in whole or in part pursuant to the terms of the Indenture, including, without limitation,
Section 13.02 and Section 13.03 of the Indenture. 
 16. The Notes are not redeemable. 

All capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Indenture. 

[Remainder of page intentionally left blank.] 

  
 - 2 -

 IN WITNESS WHEREOF, this Officers’ Certificate has been executed by the undersigned as
of date first written above. 
  

	
	
	/s/ Marc D. Hamburg
	Name: Marc D. Hamburg
	Title: Senior Vice President and Chief Financial Officer

  

	
	
	/s/ Robert P. Reeson
	Name: Robert P. Reeson
	Title: Assistant Secretary

 OFFICERS’ CERTIFICATE ESTABLISHING
TERMS OF NOTES

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]